Eli Lilly and Cipla have signed an agreement to distribute and promote tirzepatide in India under a second brand name, Yurpeak.

Under the agreement, Lilly will manufacture and supply Yurpeak to Cipla, which will distribute and promote the product to enable its broader access across the country beyond cities where Lilly already has an established presence. The price will be the same as Mounjaro.

“The introduction of a second brand of tirzepatide in India through our commercial agreement with Cipla furthers Lilly’s commitment to expanding access to innovative treatments for chronic conditions,” said Winselow Tucker, President and General Manager, Lilly India. 

“With India facing a growing burden of type 2 diabetes and obesity, broader availability of tirzepatide will ensure that more patients can benefit from this innovative therapy.”

Achin Gupta, Global Chief Operating Officer, Cipla, noted that the introduction of Yurpeak (tirzepatide) marks the company’s entry into obesity care.

“Our partnership with Lilly reflects our resolve to address one of the most pressing health concerns of our time and offer patients innovative, accessible solutions that can transform health outcomes,” he said.

Tirzepatide is a prescription-based, first and only dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, indicated as an adjunct to diet and exercise for the treatment of type 2 diabetes and chronic weight management in adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with at least one weight-related comorbidity.

Yurpeak will be available in the KwikPen presentation, a multi-dose single-patient-use prefilled pen. Each pen contains four fixed doses, administered once weekly. The pen will be available in six dose strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg, allowing healthcare professionals to personalise treatment plans to better suit individual patient needs.